| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Nestlé Research Center, Lausanne, Switzerland;
Université Catholique de Louvain, Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Brussels, Belgium; and
Institute of Molecular Medicine Rangueil (12 MR), INSERM U858, IFR31, Toulouse, France
1Correspondence: Nestlé Research Center, P.O. Box 44, CH 1000 Lausanne, Switzerland. E-mail: chieh-jason.chou{at}rdls.nestle.com
Recent data suggest that the gut microbiota plays a significant role in fat accumulation. However, it is not clear whether gut microbiota is involved in the pathophysiology of type 2 diabetes. To assess this issue, we modulated gut microbiota via antibiotics administration in two different mouse models with insulin resistance. Results from dose-determination studies showed that a combination of norfloxacin and ampicillin, at a dose of 1g/L, maximally suppressed the numbers of cecal aerobic and anaerobic bacteria in ob/ob mice. After a 2-wk intervention with the antibiotic combination, both ob/ob and diet-induced obese and insulin-resistant mice showed a significant improvement in fasting glycemia and oral glucose tolerance. The improved glycemic control was independent of food intake or adiposity because pair-fed ob/ob mice were as glucose intolerant as the control ob/ob mice. Reduced liver triglycerides and increased liver glycogen correlated with improved glucose tolerance in the treated mice. Concomitant reduction of plasma lipopolysaccharides and increase of adiponectin further supported the antidiabetic effects of the antibiotic treatment in ob/ob mice. In summary, modulation of gut microbiota ameliorated glucose tolerance of mice by altering the expression of hepatic and intestinal genes involved in inflammation and metabolism, and by changing the hormonal, inflammatory, and metabolic status of the host.—Membrez, M., Blancher, F., Jaquet, M., Bibiloni, R., Cani, P. D., Burcelin, R. G., Corthesy, I., Macé, K., Chou, C. J. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice.
Key Words: lipopolysaccharide • hepatic steatosis • liver glycogen • TNF-
This article has been cited by other articles:
|
|
 |
|
  M. Z Strowski and B. Wiedenmann Probiotic carbohydrates reduce intestinal permeability and inflammation in metabolic diseases Gut, August 1, 2009; 58(8): 1044 - 1045. [Full Text] [PDF]
|
|
|
|
|
|
P D Cani, S Possemiers, T Van de Wiele, Y Guiot, A Everard, O Rottier, L Geurts, D Naslain, A Neyrinck, D M Lambert, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability Gut, August 1, 2009; 58(8): 1091 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Antonopoulos, S. M. Huse, H. G. Morrison, T. M. Schmidt, M. L. Sogin, and V. B. Young Reproducible Community Dynamics of the Gastrointestinal Microbiota following Antibiotic Perturbation Infect. Immun., June 1, 2009; 77(6): 2367 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Mencin, J Kluwe, and R F Schwabe Toll-like receptors as targets in chronic liver diseases Gut, May 1, 2009; 58(5): 704 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Grunfeld and K. R. Feingold Endotoxin in the gut and chylomicrons: translocation or transportation? J. Lipid Res., January 1, 2009; 50(1): 1 - 2. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
